Gambaran Umum
ACADIA Pharmaceuticals Inc., based in the United States, operates primarily within the biopharmaceutical industry, focusing on the development and commercialization of medications aimed at improving the lives of patients with central nervous system disorders. The company's flagship product, Nuplazid (pimavanserine), is approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Additionally, ACADIA is involved in a range of projects targeting other CNS conditions, including schizophrenia, depression, and dementia-related psychosis. Through ongoing research and clinical trials, ACADIA strives to expand the applications of its proprietary drug, pimavanserin, while continuously exploring new therapeutic candidates to enhance its portfolio and address the unmet medical needs of CNS patients.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk ACADIA Pharmaceuticals Inc. per 2025 Jun 30 adalah 1,018.88 MM.
- Nilai operating income untuk ACADIA Pharmaceuticals Inc. per 2025 Jun 30 adalah 90.30 MM.
- Nilai net income untuk ACADIA Pharmaceuticals Inc. per 2025 Jun 30 adalah 222.16 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 1,018.88 | 90.30 | 222.16 |
2025-03-31 | 996.28 | 88.36 | 228.88 |
2024-12-31 | 957.80 | 84.28 | 226.45 |
2024-09-30 | 929.24 | 112.23 | 128.51 |
2024-06-30 | 890.53 | 22.82 | 30.57 |
2024-03-31 | 813.81 | -4.58 | -1.71 |
2023-12-31 | 726.44 | -73.38 | -61.29 |
2023-09-30 | 631.89 | -154.39 | -148.81 |
2023-06-30 | 550.90 | -127.48 | -110.81 |
2023-03-31 | 520.23 | -164.16 | -145.94 |
2022-12-31 | 517.24 | -223.60 | -215.97 |
2022-09-30 | 511.50 | -222.19 | -217.34 |
2022-06-30 | 512.40 | -206.62 | -204.62 |
2022-03-31 | 493.06 | -216.68 | -214.48 |
2021-12-31 | 484.14 | -170.44 | -167.87 |
2021-09-30 | 474.39 | -140.14 | -191.54 |
2021-06-30 | 463.36 | -210.74 | -261.74 |
2021-03-31 | 458.24 | -211.04 | -260.01 |
2020-12-31 | 441.75 | -233.79 | -281.58 |
2020-09-30 | 419.07 | -275.82 | -267.86 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 1.33.
- laba per saham yang terdilusi untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 1.33.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | 1.33 | 1.33 |
2025-03-31 | 1.38 | 1.37 |
2024-12-31 | 1.37 | 1.36 |
2024-09-30 | 0.78 | 0.78 |
2024-06-30 | 0.19 | 0.19 |
2024-03-31 | -0.01 | -0.00 |
2023-12-31 | -0.37 | -0.37 |
2023-09-30 | -0.91 | -0.91 |
2023-06-30 | -0.68 | -0.69 |
2023-03-31 | -0.90 | -0.91 |
2022-12-31 | -1.34 | -1.34 |
2022-09-30 | -1.34 | -1.34 |
2022-06-30 | -1.27 | -1.27 |
2022-03-31 | -1.33 | -1.33 |
2021-12-31 | -1.05 | |
2021-09-30 | -1.20 | -1.20 |
2021-06-30 | -1.64 | -1.64 |
2021-03-31 | -1.64 | -1.64 |
2020-12-31 | -1.79 | |
2020-09-30 | -1.72 | -1.72 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk ACADIA Pharmaceuticals Inc. per 2025 Jun 30 adalah 187.91 MM.
- Nilai cash from investing activities untuk ACADIA Pharmaceuticals Inc. per 2025 Jun 30 adalah -127.65 MM.
- Nilai kas dari aktivitas pendanaan untuk ACADIA Pharmaceuticals Inc. per 2025 Jun 30 adalah 20.03 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 187.91 | -127.65 | 20.03 |
2025-03-31 | 148.96 | -140.55 | 7.64 |
2024-12-31 | 157.72 | -30.54 | 6.84 |
2024-09-30 | 202.73 | -153.03 | 10.31 |
2024-06-30 | 80.53 | -36.47 | 22.79 |
2024-03-31 | 63.71 | -174.56 | 24.71 |
2023-12-31 | 16.70 | 32.00 | 25.13 |
2023-09-30 | -92.54 | 14.60 | 21.31 |
2023-06-30 | -34.31 | -4.07 | 8.85 |
2023-03-31 | -55.64 | 134.41 | 7.20 |
2022-12-31 | -114.03 | 73.24 | 8.20 |
2022-09-30 | -113.30 | 162.54 | 10.95 |
2022-06-30 | -129.64 | -9.22 | 11.73 |
2022-03-31 | -141.84 | 29.37 | 12.90 |
2021-12-31 | -125.66 | -71.10 | 18.16 |
2021-09-30 | -130.03 | -259.61 | 31.92 |
2021-06-30 | -135.76 | 49.71 | 42.57 |
2021-03-31 | -147.31 | 193.78 | 84.97 |
2020-12-31 | -136.17 | 192.51 | 81.00 |
2020-09-30 | -138.38 | 100.32 | 105.93 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 4.70.
- p/tbv untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 5.55.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 4.70 | 5.55 | |
2025-03-31 | 3.89 | 4.64 | |
2024-12-31 | 4.81 | 5.89 | |
2024-09-30 | 85.15 | 5.04 | 6.37 |
2024-06-30 | -1,570.08 | 5.79 | 7.59 |
2024-03-31 | 7.04 | 8.30 | |
2023-12-31 | -34.53 | 14.19 | 17.40 |
2023-09-30 | -30.76 | 8.61 | 10.41 |
2023-06-30 | -26.74 | 10.43 | 12.81 |
2023-03-31 | -14.14 | 7.63 | |
2022-12-31 | 6.05 | 6.05 | |
2022-09-30 | 6.09 | 6.09 | |
2022-06-30 | 5.13 | 5.13 | |
2022-03-31 | -23.25 | 7.22 | 7.22 |
2021-12-31 | -19.60 | 6.62 | 6.63 |
2021-09-30 | -10.20 | 4.73 | 4.73 |
2021-06-30 | |||
2021-03-31 | -11.67 | 5.22 | 5.22 |
2020-12-31 | -10.74 | 4.82 | 4.83 |
2020-09-30 | -11.23 | 4.59 | 4.61 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.09.
- EBIT (3 tahun) / EV untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.02.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | 0.09 | 0.02 |
2025-03-31 | 0.12 | 0.02 |
2024-12-31 | 0.06 | -0.02 |
2024-09-30 | 0.02 | -0.05 |
2024-06-30 | 0.01 | -0.05 |
2024-03-31 | -0.02 | -0.06 |
2023-12-31 | -0.03 | -0.04 |
2023-09-30 | -0.03 | -0.06 |
2023-06-30 | -0.04 | -0.06 |
2023-03-31 | -0.08 | -0.09 |
2022-12-31 | -0.10 | -0.10 |
2022-09-30 | -0.09 | -0.10 |
2022-06-30 | -0.12 | -0.13 |
2022-03-31 | -0.05 | -0.07 |
2021-12-31 | -0.06 | -0.07 |
2021-09-30 | -0.12 | -0.12 |
2021-06-30 | ||
2021-03-31 | -0.11 | -0.10 |
2020-12-31 | -0.12 | -0.11 |
2020-09-30 | -0.10 | -0.10 |
Efektivitas Manajemen
- roa untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.25.
- roe untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.44.
- roic untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.28.
- croic untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.02.
- ocroic untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.18.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | 0.25 | 0.44 | 0.28 | 0.02 | 0.18 |
2025-03-31 | 0.26 | 0.49 | 0.29 | 0.17 | 0.20 |
2024-12-31 | 0.17 | 0.30 | 0.21 | 0.10 | 0.32 |
2024-09-30 | 0.05 | 0.08 | 0.05 | 0.12 | 0.14 |
2024-06-30 | -0.00 | -0.00 | -0.00 | -0.16 | 0.12 |
2024-03-31 | -0.10 | -0.15 | -0.13 | 0.15 | 0.03 |
2023-12-31 | -0.25 | -0.35 | -0.35 | -0.14 | -0.22 |
2023-09-30 | -0.18 | -0.25 | -0.24 | -0.06 | -0.08 |
2023-06-30 | -0.24 | -0.34 | -0.24 | -0.06 | -0.08 |
2023-03-31 | -0.35 | -0.49 | -0.34 | 0.20 | -0.13 |
2022-12-31 | -0.30 | -0.38 | -0.44 | 0.12 | -0.23 |
2022-09-30 | -0.29 | -0.36 | -0.44 | 0.12 | -0.23 |
2022-06-30 | -0.30 | -0.38 | -0.41 | -0.25 | -0.26 |
2022-03-31 | -0.22 | -0.29 | -0.42 | -0.20 | -0.28 |
2021-12-31 | -0.24 | -0.31 | -0.28 | -0.30 | -0.21 |
2021-09-30 | -0.33 | -0.40 | -0.30 | -0.57 | -0.21 |
2021-06-30 | -0.34 | -0.39 | -0.41 | -0.07 | -0.21 |
2021-03-31 | -0.35 | -0.41 | -0.40 | 0.20 | -0.23 |
2020-12-31 | -0.36 | -0.40 | -0.42 | 0.20 | -0.20 |
2020-09-30 | -0.35 | -0.39 | -0.38 | 0.10 | -0.20 |
Gross Margins
- marjin kotor untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.60.
- marjin bersih untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.23.
- marjin operasi untuk ACADIA Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.09.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.60 | 0.23 | 0.09 |
2025-03-31 | 0.90 | 0.24 | 0.09 |
2024-12-31 | 0.63 | 0.14 | 0.12 |
2024-09-30 | 0.51 | 0.03 | 0.03 |
2024-06-30 | 0.49 | -0.00 | -0.01 |
2024-03-31 | 0.46 | -0.08 | -0.10 |
2023-12-31 | 0.39 | -0.24 | -0.24 |
2023-09-30 | 0.46 | -0.20 | -0.23 |
2023-06-30 | 0.29 | -0.20 | -0.23 |
2023-03-31 | 0.28 | -0.28 | -0.32 |
2022-12-31 | 0.29 | -0.42 | -0.43 |
2022-09-30 | 0.33 | -0.42 | -0.43 |
2022-06-30 | 0.33 | -0.40 | -0.40 |
2022-03-31 | 0.47 | -0.43 | -0.44 |
2021-12-31 | 0.57 | -0.35 | -0.35 |
2021-09-30 | 0.43 | -0.40 | -0.30 |
2021-06-30 | 0.43 | -0.56 | -0.45 |
2021-03-31 | 0.41 | -0.57 | -0.46 |
2020-12-31 | 0.98 | -0.64 | -0.53 |
2020-09-30 | 0.49 | -0.64 | -0.66 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1070494 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |